A Phase 3 interventional study of Ravulizumab and Placebo in Thrombotic Microangiopathy, sponsored by Alexion Pharmaceuticals, Inc.. Terminated at 97 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Thrombotic Microangiopathies with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Thrombotic Microangiopathies · United States.
Among the 20 studies in Thrombotic Microangiopathies with a site in United States, this one is the 10th largest by enrollment of the 14 interventional ones that give a count, is one of 4 that started in 2021, is one of 7 in phase 3, and was the 14th registered.
52 studies on the registry are indexed under Thrombotic Microangiopathies; 21 are open to participants now.
Browse Thrombotic Microangiopathies studies →3 of the 20 studies in Thrombotic Microangiopathies with a site in United States are open now. Recruiting first, the newest first:
Omeros Corporation · Sites in United States, Germany, Israel and 2 more countries
Ages 28 days–17 yrs
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages up to 24
Alexion Pharmaceuticals, Inc. · Sites in United States, Australia, Belgium and 14 more countries
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Thrombotic Microangiopathies studies recruiting now, 13 (68%) set no upper age limit and 3 (16%) stop at 75 or younger; 9 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 40 across 24 interventional studies indexed under Thrombotic Microangiopathies.
Median enrollment 24 across the 14 interventional studies, 254 across the 6 observational. Of the 14 that completed or were terminated, 9 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
AstraZeneca has 6 studies filed under Thrombotic Microangiopathies — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Thrombotic Microangiopathies with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will investigate the efficacy and safety of ravulizumab compared to placebo in adult participants with thrombotic microangiopathy (TMA) associated with a trigger. Participants will be randomized to receive either ravulizumab plus best supportive care or placebo plus best supportive care. The treatment period is 26 weeks followed by a 26-week off-treatment follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Ravulizumab · Other: Best Supportive Care
Other: Placebo · Other: Best Supportive Care
Body weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.
Also known as: Ultomiris, ALXN1210
Matching placebo
Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
Number of Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26
TMA response required the following: 1) Normalization of platelet count without transfusion support during the prior 7 days. 2) Normalization of LDH. 3) Improvement in glomerular filtration rate (eGFR) of \>= 30% compared to baseline. Participants must meet each TMA criterion at 2 separate assessments obtained at least 24 hours apart, and any measurement in between.
Time frame: Week 26
Time to Complete TMA Response
The Kaplan-Meier estimate of time to event of complete TMA response is reported. TMA response required the following: 1) Normalization of platelet count without transfusion support during the prior 7 days. 2) Normalization of LDH. 3) Improvement in eGFR of \>= 30% compared to baseline. Participants must meet each TMA criterion at 2 separate assessments obtained at least 24 hours apart, and any measurement in between. Participants who did not have a response were censored at the date of last visit or study discontinuation at the time when the analysis was performed.
Time frame: Baseline through Week 26
Number of Participants With Hematologic Response at Week 26
Hematologic response required the following: (1) Normalization of platelet count without transfusion support during the prior 7 days, and (2) normalization of LDH.
Time frame: Week 26
Number of Participants With Renal Response at Week 26
Renal response is improvement in eGFR of \>= 30% compared to baseline. If a participant is on dialysis ≤5 days prior to the date of eGFR assessment, the eGFR will be set to 10 milliliter/minute/1.73 meter square (mL/min/1.73 m\^2) for that assessment. If a participant is on dialysis during the entire 26 week randomized Treatment Period, or through early discontinuation of study drug, then the change in eGFR was not calculated.
Time frame: Week 26
Number of Participants On Dialysis at Week 26
Time frame: Week 26
Change From Baseline in eGFR at Week 26
If a participant is on dialysis during the entire 26 week randomized Treatment Period, or through early discontinuation of study drug, then the change in eGFR was not calculated.
Time frame: Baseline, Week 26
| Milestone | Ravulizumab | Placebo |
|---|---|---|
| Started | 9 | 7 |
| Received at least 1 dose of study drug | 9 | 7 |
| Completed | 4 | 1 |
| Not completed | 5 | 6 |
| Withdrew: Other | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Study terminated by sponsor | 1 | 4 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Death | 3 | 0 |
TMA response required the following: 1) Normalization of platelet count without transfusion support during the prior 7 days. 2) Normalization of LDH. 3) Improvement in glomerular filtration rate (eGFR) of \>= 30% compared to baseline. Participants must meet each TMA criterion at 2 separate assessments obtained at least 24 hours apart, and any measurement in between.
| Participants | Ravulizumab | Placebo |
|---|---|---|
| Number of Participants With Complete Thrombotic Microangiopathy (TMA) Response at Week 26 | 2 | 3 |
The Kaplan-Meier estimate of time to event of complete TMA response is reported. TMA response required the following: 1) Normalization of platelet count without transfusion support during the prior 7 days. 2) Normalization of LDH. 3) Improvement in eGFR of \>= 30% compared to baseline. Participants must meet each TMA criterion at 2 separate assessments obtained at least 24 hours apart, and any measurement in between. Participants who did not have a response were censored at the date of last visit or study discontinuation at the time when the analysis was performed.
| days | Ravulizumab | Placebo |
|---|---|---|
| Time to Complete TMA Response | NA (21.0 to NA) | NA (16.0 to NA) |
Hematologic response required the following: (1) Normalization of platelet count without transfusion support during the prior 7 days, and (2) normalization of LDH.
| Participants | Ravulizumab | Placebo |
|---|---|---|
| Number of Participants With Hematologic Response at Week 26 | 5 | 6 |
Renal response is improvement in eGFR of \>= 30% compared to baseline. If a participant is on dialysis ≤5 days prior to the date of eGFR assessment, the eGFR will be set to 10 milliliter/minute/1.73 meter square (mL/min/1.73 m\^2) for that assessment. If a participant is on dialysis during the entire 26 week randomized Treatment Period, or through early discontinuation of study drug, then the change in eGFR was not calculated.
| Participants | Ravulizumab | Placebo |
|---|---|---|
| Number of Participants With Renal Response at Week 26 | 4 | 4 |
| Participants | Ravulizumab | Placebo |
|---|---|---|
| Number of Participants On Dialysis at Week 26 | 1 | 0 |
If a participant is on dialysis during the entire 26 week randomized Treatment Period, or through early discontinuation of study drug, then the change in eGFR was not calculated.
| milliliter/minute/1.73 meter^2 | Ravulizumab | Placebo |
|---|---|---|
| Change From Baseline in eGFR at Week 26 | 25.8 ± 19.90 | 17.5 ± 7.59 |
Collected over Baseline up to Week 34. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ravulizumab | 3/9 (33.3%) | 6/9 (66.7%) | 9/9 (100%) |
| Placebo | 0/7 (0%) | 3/7 (42.9%) | 7/7 (100%) |
| Event | Ravulizumab | Placebo |
|---|---|---|
| Escherichia urinary tract infectionInfections and infestations | 0/9 | 1/7 |
| SepsisInfections and infestations | 0/9 | 1/7 |
| Metastases to boneNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/9 | 1/7 |
| Prostate cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/9 | 1/7 |
| Toxic epidermal necrolysisSkin and subcutaneous tissue disorders | 0/9 | 1/7 |
| COVID-19 pneumoniaInfections and infestations | 1/9 | 0/7 |
| Epstein-Barr viraemiaInfections and infestations | 1/9 | 0/7 |
| PneumoniaInfections and infestations | 1/9 | 0/7 |
| Urinary tract infectionInfections and infestations | 1/9 | 0/7 |
| Ischaemic strokeNervous system disorders | 1/9 | 0/7 |
| Event | Ravulizumab | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 2/9 | 4/7 |
| VomitingGastrointestinal disorders | 2/9 | 3/7 |
| COVID-19Infections and infestations | 2/9 | 3/7 |
| AnaemiaBlood and lymphatic system disorders | 3/9 | 0/7 |
| DiarrhoeaGastrointestinal disorders | 1/9 | 2/7 |
| PyrexiaGeneral disorders | 2/9 | 2/7 |
| HypertensionVascular disorders | 2/9 | 2/7 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/9 | 2/7 |
| Enterococcal infectionInfections and infestations | 2/9 | 0/7 |
| PneumoniaInfections and infestations | 2/9 | 0/7 |
The Modified Intent-to-Treat Analysis Set included all randomized participants, excluding participants who enrolled prior to availability of ST-HUS and ADAMTS13 central laboratory results and were subsequently found to be ineligible after randomization.
| Age, Continuous(years) | Ravulizumab | Placebo | Total |
|---|---|---|---|
| Mean | 48.2 ± 15.75 | 57.7 ± 17.70 | 52.4 ± 16.77 |
| Sex: Female, Male(Participants) | Ravulizumab | Placebo | Total |
|---|---|---|---|
| Female | 6 | 4 | 10 |
| Male | 3 | 3 | 6 |
| Ethnicity (NIH/OMB)(Participants) | Ravulizumab | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 3 | 5 |
| Not Hispanic or Latino | 6 | 3 | 9 |
| Unknown or Not Reported | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Ravulizumab | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 6 | 3 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 2 | 3 | 5 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 1 | 2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2021 to primary completion in Dec 2022, 17 months.
Results were first posted in Dec 2023, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ravulizumab
Thrombotic Microangiopathies →
Alexion Pharmaceuticals, Inc. →